2024
Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury
Lisi I, Moro F, Mazzone E, Marklund N, Pischiutta F, Kobeissy F, Mao X, Corrigan F, Helmy A, Nasrallah F, Di Pietro V, Ngwenya L, Portela L, Semple B, Schneider A, Diaz Arrastia R, Menon D, Smith D, Wellington C, Loane D, Wang K, Zanier E, Abbasloo E, Agrawal A, Anwer M, Anyaegbu C, Caeyenberghs K, Collins L, Corrigan F, Cowen G, Portela L, Cullen J, D'Alonzo B, Di Pietro V, Keene C, Esser M, Giersztein S, Helmy A, Hoffman S, Iacono D, Jha R, Johnson V, Justus J, Keene C, Lins B, Liebel S, Loane D, Mao X, Marklund N, McCrea M, McGuone D, Mohamed A, Moro F, Mychasiuk R, Nagarajan G, Nasrallah F, Ngum P, Ngwenya L, Oteng R, Parihar A, Phillips J, Pischiutta F, Prakash S, Robba C, Rostami E, Roselli F, Semple B, Shultz S, Smith D, Song H, Stefani M, Stewart W, Verma R, Wang K, Wellington C, Winston B, Zanier E. Exploiting blood-based biomarkers to align preclinical models with human traumatic brain injury. Brain 2024, awae350. PMID: 39514789, DOI: 10.1093/brain/awae350.Peer-Reviewed Original ResearchTraumatic brain injuryPreclinical modelsPreclinical studiesRodent modelsUCH-L1Experience traumatic brain injuriesBrain injuryReal world clinical practiceTranslation of drugsPost-injuryClinically relevant biomarkersPathophysiology of traumatic brain injuryHuman traumatic brain injuryWhite matter lossDose optimizationBlood-based biomarkersMedian quality scoreTreatment initiationTBI studiesTherapeutic decisionsDrug dose optimizationPharmacodynamic responseChronic phaseBlood levelsClinical trials
2023
Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury
Kapate N, Liao R, Sodemann R, Stinson T, Prakash S, Kumbhojkar N, Suja V, Wang L, Flanz M, Rajeev R, Villafuerte D, Shaha S, Janes M, Park K, Dunne M, Golemb B, Hone A, Adebowale K, Clegg J, Slate A, McGuone D, Costine-Bartell B, Mitragotri S. Backpack-mediated anti-inflammatory macrophage cell therapy for the treatment of traumatic brain injury. PNAS Nexus 2023, 3: pgad434. PMID: 38187808, PMCID: PMC10768983, DOI: 10.1093/pnasnexus/pgad434.Peer-Reviewed Original ResearchTraumatic brain injuryBrain injuryAnti-inflammatory interleukin-4Cortical impact (CCI) TBI modelCell therapyAcute clinical managementDysregulated inflammatory responseSecondary brain injuryAnti-inflammatory phenotypeBrain lesion siteImmune cell therapyRole of macrophagesLarge animal modelUnique therapeutic potentialWound-healing phenotypeRampant inflammationProinflammatory biomarkersTBI modelImmunomodulatory effectsInflammation modulationCurrent therapiesMacrophage-based therapiesNeuroprotection mechanismsProinflammatory activationSerum concentrationsA PILOT STUDY: SPATIOTEMPORALLY-RESOLVED MOLECULAR MECHANISMS OF ACUTE IMMUNE AND NEUROMODULATORY RESPONSES TO TRAUMATIC BRAIN INJURY
Mohammed F, Mcguone D, Omay S, Omay Z, Zhou J. A PILOT STUDY: SPATIOTEMPORALLY-RESOLVED MOLECULAR MECHANISMS OF ACUTE IMMUNE AND NEUROMODULATORY RESPONSES TO TRAUMATIC BRAIN INJURY. IBRO Neuroscience Reports 2023, 15: s189-s190. DOI: 10.1016/j.ibneur.2023.08.289.Peer-Reviewed Original Research